Liangbo Shen

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Aims To investigate the long-term natural history of ellipsoid zone (EZ) width in USH2A -retinopathy. Methods EZ width measurements from optical coherence tomography were retrospectively obtained from 110 eyes of 55 participants with molecularly confirmed biallelic USH2A -retinopathy. We used a hierarchical Bayesian method to construct and compare different mathematical models describing the long-term decline of EZ width. Results Compared with linear and quadratic models, exponential decline best represented the long-term loss of EZ width based on the deviance information criterion score. Log-transformed EZ width declined linearly over 30 years of inferred disease duration (median: 0.063 (IQR: 0.040–0.086) log (µm)/year). Compared with the raw EZ width decline rate, the log-transformed EZ width decline rate required 48% fewer patients to achieve an identically powered 1-year trial (38 vs 73 participants). Log EZ width decline rate was uncoupled from baseline EZ width (Spearman ρ=−0.18, p=0.06) and age (ρ=−0.10, p=0.31). Eyes with Usher syndrome exhibited earlier median onset ages of macular EZ width loss (18.8 (IQR: 13.1–24.7) vs 28.1 (IQR: 18.5–35.8) years, p<0.001) but comparable log EZ width decline rates (0.060 (IQR: 0.035–0.100) vs 0.065 (IQR: 0.050–0.079) log (µm)/year; p=0.42). Conclusions EZ width follows an exponential decline in USH2A -retinopathy. Compared with raw EZ width decline rate, log-transformed EZ width decline rate may be a superior endpoint for clinical trials. Syndromic eyes exhibit an earlier onset of macular EZ width loss but progress at comparable rates to non-syndromic eyes.

Year:

2025

Year:

2025

Background Anterior chamber (AC) paracentesis is a valuable diagnostic and therapeutic ophthalmic procedure, but the conventional technique poses ergonomic and safety challenges. Methods We developed a custom, low-cost, 3D-printed syringe handle that enables one-handed AC paracentesis using standard 1-mL syringes by allowing single-finger plunger retraction. In a randomized controlled wet-lab study, ten ophthalmology residents each performed four AC paracentesis procedures (two with the novel device, two with the conventional technique) on porcine eyes. The primary outcome was successful aspiration of ≥ 100 µL of aqueous humor. Secondary outcomes included intraocular injury, aspirated volume, procedure time, and responses to an anonymous post-procedure survey. Results All AC paracentesis procedures achieved ≥ 100 µL of fluid. No intraocular injuries occurred with the novel device, compared to 2 intraocular tissue contacts with the conventional method. The median aspirated volume was 120 µL (interquartile range [IQR]: 110–150 µL) with the novel device, close to the 100 µL threshold, with no extractions exceeding 200 µL. In contrast, the conventional method yielded a significantly higher median volume of 200 µL (IQR 140–270 µL; P < 0.001), with 25% of procedures exceeding 250 µL. The median procedure time was 26.9 s with the novel device versus 35.7 s with the conventional method, a 8.8 s (25%) reduction ( P = 0.13). Participants generally preferred the novel device for ease of use, control, and perceived safety. Nine of 10 participants reported feeling more or much more confident about performing AC paracentesis safely with the novel syringe handle than with the conventional technique. Conclusions We developed a novel syringe handle for one-handed AC paracentesis, which improved the safety and precision of the procedure while reducing procedural time. Its low-cost, reusable design and compatibility with standard syringes make it a practical tool for the procedure. Further clinical studies are warranted to explore broader applications.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (7)

Philip Rosenfeld

Professor of Ophthalmology

University of Miami Health System

UNITED STATES
View details

Jeremy Keenan

University of California, San Francisco

UNITED STATES
View details

Tiarnan Keenan

National Institutes of Health

UNITED STATES
View details

Mariya Moosajee

Professor and Group Leader

The Francis Crick Institute

UNITED KINGDOM
View details

Jacquelyn Callander

Clinical Assistant Professor

Stanford University

UNITED STATES
View details

Minali Prasad

Boston University

UNITED STATES
View details

Emily Chew

NIH Distinguished Investigator

-

UNITED STATES
View details